Transition Bio

Transition Bio is a drug discovery platform company that combines proprietary microfluidics technology, machine learning, and deep expertise in biophysics to target intrinsically disordered proteins (IDPs) and biomolecular condensates — biological structures implicated in cancer, neurodegeneration, and other diseases. Founded by leading scientists from Harvard University and the University of Cambridge, the company integrates advances in physics, chemistry, biology, and machine learning to solve fundamental challenges in health and disease. Transition Bio operates dual laboratories in Cambridge, Massachusetts, USA and Cambridge, UK, and its leadership team brings extensive experience from biopharmaceutical companies including AstraZeneca, Radius Health, and Elan Corporation.